Avadel Pharmaceuticals (AVDL) announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled “A New Dawn in the Management of Narcolepsy”. “I am delighted to serve as guest editor for the recently published CNS Drugs supplement, focused on key clinical issues for people with narcolepsy and their clinicians with a particular emphasis on sodium oxybate therapy, an underutilized treatment option,” said Michael Thorpy, M.D., an investigator for the Phase 3 REST-ON trial of LUMRYZ, Director at the Sleep-Wake Disorders Center at Montefiore Medical Center and Professor of Neurology at the Albert Einstein College of Medicine. “This supplement provides clinicians with important information about how to optimize therapy to help address narcolepsy symptoms, including new analyses of onset of efficacy and practical considerations for use of a once-nightly sodium oxybate therapy, to enable clinicians to set proper expectations when initiating LUMRYZ therapy.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Positioned for Growth: Buy Rating Affirmed by Analyst Marc Goodman
- Avadel Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
- Geopolitical Shifts Threaten Avadel Pharmaceuticals’ Financial Stability
- Avadel Pharmaceuticals Reports Strong Growth in 2024
- Avadel Pharmaceuticals sees FY25 net product revenue $240M-$260M